Aquestive Therapeutics (AQST) to Release Earnings on Wednesday

Aquestive Therapeutics (NASDAQ:AQST) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Aquestive Therapeutics to post earnings of ($0.13) per share and revenue of $13.2840 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:00 AM ET.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $4.09 on Wednesday. The firm has a market cap of $498.98 million, a P/E ratio of -5.76 and a beta of 1.65. Aquestive Therapeutics has a 52 week low of $2.12 and a 52 week high of $7.55. The firm’s 50-day simple moving average is $4.49 and its 200 day simple moving average is $5.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AQST. NewEdge Advisors LLC acquired a new stake in Aquestive Therapeutics during the third quarter worth about $28,000. BNP Paribas Financial Markets lifted its holdings in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $33,000. Kestra Private Wealth Services LLC bought a new position in Aquestive Therapeutics in the third quarter valued at approximately $60,000. Finally, Victory Capital Management Inc. increased its stake in Aquestive Therapeutics by 17.0% in the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after acquiring an additional 1,862 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AQST. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a report on Tuesday, February 3rd. Piper Sandler increased their price objective on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $8.50.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.